



Angel Investment Forum Provides “Series Seed” Funding to NeuroEM Therapeutics to Support Development of Medical Device against Alzheimer’s Disease

Phoenix, AZ (May 2nd, 2016) Angel Investment Forum (AIF), a premiere group of Angel investors based in Connecticut, is providing “Series Seed” funding to NeuroEM Therapeutics in support of the company’s development of Transcranial Electromagnetic Treatment (TEMT) against Alzheimer’s Disease. NeuroEM Therapeutics, a Phoenix-based medical device company, is designing and fabricating a TEMT head device based on its proprietary technology. The head devices will be utilized in an up-coming Phase I clinical trial to treat Alzheimer’s patients.

“NeuroEM is most pleased to have the support of such an esteemed group of investors as AIF”, said Dr. Gary Arendash, Founder and CEO of NeuroEM Therapeutics. “Because AIF is very selective in its investments, their funding to NeuroEM’s novel approach against Alzheimer’s Disease is particularly gratifying”. The funds will be used for operational expenses, ancillary support to the Phase I clinical trial, as well as for initiating a pilot study with Arizona State University to further investigate the mechanisms of TEMT action.

NeuroEM’s technology and its resulting TEMT head device are based on years of pre-clinical studies performed by Dr. Arendash and his colleagues, which demonstrated the ability of TEMT to protect against and reverse memory impairment in animal models for Alzheimer’s Disease. The TEMT head device itself was conceived by NeuroEM, with conception of a related head device by Remarkable Technologies, Inc. (Eric Knight, CEO), with whom NeuroEM has an exclusive licensing agreement.

“AIF is pleased to support NeuroEM’s first human trials of its novel device to treat Alzheimer’s disease” said Edward C Goodwin PhD, President of AIF. “Despite 5.4 million sufferers in the U.S. and annual costs of some \$230 billion, Alzheimer’s remains a major unmet medical need. One of our members, Eric Knight, was so impressed with Dr. Arendash’s technology and its potential to treat Alzheimer’s that he developed and patented an application of that technology in the form of a head device for human use. Mr. Knight also led our due diligence efforts in evaluating this investment opportunity. While we normally would not invest so far from our base in Connecticut, this opportunity was so large and the problem so profound that we felt compelled to act.”

There is currently no effective treatment for Alzheimer’s disease, with current Alzheimer’s drugs simply masking the disease’s symptoms for up to one year, if at all. Moreover, all clinical trials investigating potential new drugs to treat Alzheimer’s Disease have been unsuccessful. “Since

drugs haven't worked, it is time to think outside the box for Alzheimer's therapeutics", explained Dr. Arendash. He indicated that various neuromodulatory approaches against the disease are being investigated, such as transcranial magnetic stimulation and deep brain stimulation. "Although TEMT has not been around as long as these other approaches, our pre-clinical studies suggest that TEMT may be disease-modifying, and through several complementary mechanisms" stated Dr. Arendash.

"In addition to their financial support, NeuroEM looks forward to the guidance that the experienced members of AIF can provide in moving the company forward" said Dr. Arendash. "AIF and NeuroEM share the same goal of finding an effective therapeutic against Alzheimer's Disease as quickly as possible – NeuroEM's clinical studies in the next few years will determine if TEMT is indeed that therapeutic".

About NeuroEM Therapeutics, Inc.

NeuroEM Therapeutics is a medical device company focused on development of Transcranial Electromagnetic Treatment (TEMT) to treat neurodegenerative disorders such as Alzheimer's Disease, Traumatic Brain Injury, and Down's Syndrome. The company is headquartered in Phoenix, AZ, which is a hub of both pre-clinical and clinical investigation into neurodegenerative disorders and diseases. As such, NeuroEM Therapeutics is collaborating with leading institutions in the Phoenix area such as Banner Sun Health Research Institute, Banner Alzheimer's Institute, and Arizona State University. For more information about NeuroEM Therapeutics, go to www.neuroem.com.

Forward-Looking Statements

This communication contains certain forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of NeuroEM Therapeutics, are based on management's current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements.